Evvy Just Raised $40 Million to Make Vaginal Health Testing Routine
Evvy has raised $40 million to grow its women's health testing. The Series B was led by Catalio Capital Management and announced Tuesday, September 15, 2026. TechCrunch
Evvy was started in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro. Jain is chief executive. The company says it serves more than 100,000 patients across the United States and works with 3,000 practitioners.
Its main product is an at-home vaginal swab test. It uses a lab method called metagenomic next-generation sequencing, or mNGS, which reads all microbe DNA in the sample at once, like taking a census. Evvy says the test is CLIA-certified and CLEP-certified for lab quality and finds more than 700 bacteria and fungi. Each result is reviewed by a licensed clinician and comes with a personal care plan that can include prescriptions where eligible. Evvy also offers a membership to track how treatment and daily habits change the vaginal microbiome over time. Evvy
Catalio Capital Management, a New York-based firm focused on healthcare investing across private, public and credit markets, led the round. New investors include the U.S. Fertility Innovation Fund, Rethink Impact and Muse Capital. SiliconANGLE
Evvy plans to move its platform into reproductive care, starting with fertility and IVF. The goal is to make vaginal microbiome testing routine. Beauty Independent
That medical growth is linked to research using the same lab system. Evvy says it has produced 15 peer-reviewed publications and abstracts. It says it found new subtypes of bacterial vaginosis and hundreds of vaginal microbe genomes that had not been catalogued before.
On products, Evvy in May launched EvvyAI, an AI assistant described as an advisor for vaginal health. It also started a prospective study that uses its tests in IVF clinics.
The broader context here is common in testing. One at-home swab can start the relationship with a patient. Repeat tests, clinician review and prescriptions keep it going. Research then makes each new sample more valuable.
Looking at what this means for fertility care, the IVF focus is practical. Clinics already use clear plans with measurable results. Adding microbiome testing adds detailed data at set times. It also sends Evvy patients through doctors, not only online sales.
In my view, the key bet combines deep lab data with an AI helper and human clinician review. Automated help eases the path for patients with symptoms that return. Clinician review keeps it checked. Whether that mix works across thousands of practitioners depends on behind-the-scenes work, including how results fit medical records, how easy they are to understand and when to refer for more care. If Evvy gets that right, this testing could become a normal part of care and give doctors clearer data for problems long treated with blunt tools.
